Rapport Therapeutics, Inc. - Common Stock (RAPP)

Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.

Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.

The company is working on a treatment for a form of epilepsy that tends to be difficult to control.

Rapport Therapeutics' RAP-219 cut seizures significantly in a Phase 2a trial, with strong results and a favorable safety profile driving next steps.

After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Rapport Therapeutics reports Q2 2025 net loss of $26.7M ($0.75/share), beating estimates. Focus remains on Phase 2a trial for RAP-219 in epilepsy, with results expected in September. Cash reserves extend to 2026.

Three relatively unknown biopharma firms receive near-unanimous approval from analysts for their promising drug candidates in development.

Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session.

Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.